A retrospective, observational, cohort study evaluating changes in weight and lipid profile after switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in Taiwanese patients
Latest Information Update: 27 May 2020
At a glance
- Drugs Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide (Primary)
- Indications HIV infections
- Focus Adverse reactions
Most Recent Events
- 27 May 2020 New trial record